866-997-4948(US-Canada Toll Free)

Streptococcus Pyogenes Infections - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Diseases & Conditions

No. of Pages : 32 Pages

Streptococcus Pyogenes Infections - Pipeline Review, H1 2014

Summary

Global Markets Directs, Streptococcus Pyogenes Infections - Pipeline Review, H1 2014, provides an overview of the Streptococcus Pyogenes Infectionss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Streptococcus Pyogenes Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pyogenes Infections and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Streptococcus Pyogenes Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Streptococcus Pyogenes Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Streptococcus Pyogenes Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Streptococcus Pyogenes Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Streptococcus Pyogenes Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Streptococcus Pyogenes Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Streptococcus Pyogenes Infections Overview 6
Therapeutics Development 7
Pipeline Products for Streptococcus Pyogenes Infections - Overview 7
Pipeline Products for Streptococcus Pyogenes Infections - Comparative Analysis 8
Streptococcus Pyogenes Infections - Therapeutics under Development by Companies 9
Streptococcus Pyogenes Infections - Therapeutics under Investigation by Universities/Institutes 11
Streptococcus Pyogenes Infections - Pipeline Products Glance 12
Early Stage Products 12
Streptococcus Pyogenes Infections - Products under Development by Companies 13
Streptococcus Pyogenes Infections - Products under Investigation by Universities/Institutes 14
Streptococcus Pyogenes Infections - Companies Involved in Therapeutics Development 15
Dainippon Sumitomo Pharma Co., Ltd. 15
GlycoVaxyn AG 16
Wellstat Vaccines, LLC 17
Streptococcus Pyogenes Infections - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Molecule Type 22
Drug Profiles 24
SM-295291 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
SM-369926 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Group A Streptococcus Vaccine - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Group A Streptococcus Vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Vaccine Targeting GAC for Group A Streptococcus Infections - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Streptococcus Pyogenes Infections - Dormant Projects 29
Streptococcus Pyogenes Infections - Product Development Milestones 30
Featured News & Press Releases 30
Dec 19, 2012: GlycoVaxyn Announces Strategic Collaboration with GSK to Develop New Bacterial Vaccines using GlycoVaxyns Bio-Conjugation Technology 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Table

List of Tables
Number of Products under Development for Streptococcus Pyogenes Infections, H1 2014 7
Number of Products under Development for Streptococcus Pyogenes Infections - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Streptococcus Pyogenes Infections - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 15
Streptococcus Pyogenes Infections - Pipeline by GlycoVaxyn AG, H1 2014 16
Streptococcus Pyogenes Infections - Pipeline by Wellstat Vaccines, LLC, H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 21
Number of Products by Stage and Molecule Type, H1 2014 23
Streptococcus Pyogenes Infections - Dormant Projects, H1 2014 29

List of Chart

List of Figures
Number of Products under Development for Streptococcus Pyogenes Infections, H1 2014 7
Number of Products under Development for Streptococcus Pyogenes Infections - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Molecule Type, H1 2014 22
Number of Products by Stage and Top 10 Molecule Type, H1 2014 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *